JOHNSON & JOHNSON

For the period ended Dec 31, 2023. Filed Feb 16, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 16, 2024

JNJ$285.75+0.8%Stored close · as of Nov 13, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated statements of equity

Checking your notes…

Johnson & Johnson and subsidiaries consolidated statements of equity

	Total	RetainedEarnings and Additional paid-in capital	AccumulatedOtherComprehensiveIncome (Loss)	Common StockIssuedAmount	TreasuryStockAmount
Balance, January 3, 2021	$63,278	113,890	(15,242)	3,120	(38,490)
Net earnings	20,878	20,878
Cash dividends paid ($4.19 per share)	(11,032)	(11,032)
Employee compensation and stock option plans	2,171	(676)			2,847
Repurchase of common stock	(3,456)				(3,456)
Other comprehensive income (loss), net of tax	2,184		2,184
Balance, January 2, 2022	74,023	123,060	(13,058)	3,120	(39,099)
Net earnings	17,941	17,941
Cash dividends paid ($4.45 per share)	(11,682)	(11,682)
Employee compensation and stock option plans	2,466	(974)			3,440
Repurchase of common stock	(6,035)				(6,035)
Other comprehensive income (loss), net of tax	91		91
Balance, January 1, 2023	76,804	128,345	(12,967)	3,120	(41,694)
Net earnings	35,153	35,153
Cash dividends paid ($4.70 per share)	(11,770)	(11,770)
Employee compensation and stock option plans	2,193	(336)			2,529
Repurchase of common stock	(5,054)				(5,054)
Other	(25)				(25)
Kenvue Separation /IPO (Note 21)	(23,786)	2,451	5,181		(31,418)
Other comprehensive income (loss), net of tax	(4,741)		(4,741)
Balance, December 31, 2023	$68,774	153,843	(12,527)	3,120	(75,662)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.